Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANS014004 + PLB1004 in EGFR+ NSCLC
NCT07285148Phase 2Not yet recruiting
- Sponsor
- Beijing Pearl Biotechnology Co., Ltd.
- Start
- Jun 2026
- Primary completion
- Dec 2029
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of ANS014004 in non-small cell lung cancer (NSCLC), sponsored by Beijing Pearl Biotechnology Co., Ltd.. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
ANS014004
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07285148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07285148.